In preclinical models, stimulation with HGF is able to rescue cetuximab-sensitive CRC cell lines from EGFR inhibition in a dose-dependent manner through MET-induced activation of the AKT and MAPK pathways, even in absence of MET amplification [47]. This evidence concerns the gene HGF and colorectal carcinoma.